Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

AMPE | Ampio Pharmaceuticals Inc

Index	-	P/E	-	EPS (ttm)	-19.03	Insider Own	9.68%	Shs Outstand	0.76M	Perf Week	-13.68%
Market Cap	3.07M	Forward P/E	-	EPS next Y	-24.00	Insider Trans	433.27%	Shs Float	0.68M	Perf Month	3.06%
Income	-13.98M	PEG	-	EPS next Q	-0.02	Inst Own	3.14%	Short Float / Ratio	3.13% / 0.67	Perf Quarter	-12.78%
Sales	0.00M	P/S	-	EPS this Y	20.00%	Inst Trans	-	Short Interest	0.02M	Perf Half Y	-19.20%
Book/sh	8.69	P/B	0.47	EPS next Y	0.00%	ROA	-76.89%	Target Price	-	Perf Year	-82.76%
Cash/sh	9.14	P/C	0.44	EPS next 5Y	-	ROE	-104.89%	52W Range	3.35 - 23.73	Perf YTD	-10.30%
Dividend	-	P/FCF	-	EPS past 5Y	34.16%	ROI	-210.10%	52W High	-82.98%	Beta	1.73
Dividend %	-	Quick Ratio	3.67	Sales past 5Y	0.00%	Gross Margin	-	52W Low	20.45%	ATR	0.45
Employees	13	Current Ratio	3.67	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	46.56	Volatility	11.42% 12.23%
Optionable	No	Debt/Eq	0.07	EPS Q/Q	33.89%	Profit Margin	-	Rel Volume	0.10	Prev Close	4.06
Shortable	Yes	LT Debt/Eq	0.01	Earnings	-	Payout	-	Avg Volume	31.94K	Price	4.04
Recom	-	SMA20	-1.95%	SMA50	-6.43%	SMA200	-19.00%	Volume	1,554	Change	-0.49%

Aug-31-23 06:30AM	Ampio Pharmaceuticals Announces Reverse Stock Split (PR Newswire) +10.86%
May-26-23 04:40PM	Ampio Pharmaceuticals Announces Series D Preferred Stock Dividend to its Holders of Common Stock (PR Newswire)
Apr-18-23 06:30AM	AMPIO PHARMACEUTICALS ISSUES LETTER TO STOCKHOLDERS (PR Newswire) +22.19%
Jan-17-23 08:20AM	AMPIO PHARMACEUTICALS ISSUES LETTER TO STOCKHOLDERS (PR Newswire) -7.28%
Dec-27-22 05:44PM	Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards (PR Newswire) -6.21%
04:53PM	Loading…
Nov-17-22 04:53PM	Ampio Pharmaceuticals Announces NYSE American Removal of Trading Suspension (PR Newswire) +12.62%
Nov-08-22 04:30PM	Ampio Pharmaceuticals Announces Fifteen-to-One Reverse Stock Split (PR Newswire) -26.14%
Oct-14-22 04:01PM	Ampio Pharmaceuticals Issues Letter to Stockholders (PR Newswire) -7.84%
Oct-04-22 08:50AM	Ampio Pharmaceuticals Announces NYSE American Has Commenced Delisting Proceedings (PR Newswire) -64.90%
Jul-24-22 08:41AM	6 Penny Stocks With 1,000% Upside Potential (InvestorPlace)
Jun-02-22 04:30PM	Ampio Pharmaceuticals' CEO Mike Martino Issues Letter to Stockholders (PR Newswire) +7.22%
May-17-22 11:34AM	Ampio's Independent Committee Launches Investigation Related To AP-013 Trial (Benzinga)
May-16-22 04:10PM	Ampio Pharmaceuticals Reports First-Quarter Financial Results (PR Newswire) -6.74%
04:05PM	Ampio Independent Committee to Conduct Investigation (PR Newswire)
Apr-27-22 04:45PM	Ampio Pharmaceuticals, Inc. to Hold Conference Call (PR Newswire)
05:49PM	Loading…
Apr-20-22 05:49PM	AMPIO PROVIDES REGULATORY UPDATE (PR Newswire) -5.05%

Ampio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease. The company was founded by David Bar-Or in December 2008 and is headquartered in Englewood, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BUCHI J KEVIN	Director	Jun 09	Buy	0.29	21,858	6,284	146,858	Jun 13 12:07 PM
BUCHI J KEVIN	Director	Jun 08	Buy	0.30	25,000	7,400	125,000	Jun 09 02:26 PM
MARTINO MICHAEL A	CEO	May 24	Buy	0.29	76,890	22,121	76,890	May 26 01:30 PM
BUCHI J KEVIN	Director	May 16	Buy	0.27	32,534	8,924	100,000	May 17 04:25 PM
BUCHI J KEVIN	Director	May 15	Buy	0.25	44,026	10,857	67,466	May 16 03:30 PM
Stevens David R	Director	May 12	Buy	0.22	45,000	9,900	103,971	May 12 05:26 PM
BUCHI J KEVIN	Director	May 12	Buy	0.24	23,440	5,513	23,440	May 16 03:30 PM
Stevens David R	Director	May 11	Buy	0.22	50,000	10,875	58,971	May 12 05:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AMPE | Ampio Pharmaceuticals Inc

Upgrade your FINVIZ experience